Reviewers combined data when possible using meta-analysis and assessed the risk of bias and quality of studies according to established methods.
Relapse is defined as the return of depressive symptoms during the acute or continuation phases and is therefore considered part of the same depressive episode, whereas recurrence is defined as the return of depressive symptoms during the maintenance phase and is considered a new, distinct episode.Response to treatment (typically defined as ≥50% reduction in measured severity) can be quantified using various tools, such as the Patient Health Questionnaire-9 (PHQ-9) (7) or the Hamilton Depression Rating Scale (HAM-D) (8).The estimated economic burden associated with depression was .1 billion in 2000 and is probably higher today (2).Depressive disorders include major depressive disorder (MDD); dysthymia; and subsyndromal depression, including minor depression.Reviewers searched several databases for studies published in English, German, or Italian from 1 January 1990 through September 2015.
Studies on efficacy were limited to randomized, controlled trials and systematic reviews and meta-analyses, although evidence on harms included observational studies.
Various treatment approaches can be used to manage MDD, such as psychotherapy, complementary and alternative medicine (CAM), exercise, and pharmacotherapy.
The psychological interventions used to treat depression include acceptance and commitment therapy, cognitive therapy, cognitive behavioral therapy (CBT), interpersonal therapy, and psychodynamic therapies (Table 1).
Individuals who served on the Clinical Guidelines Committee from initiation of the project until its approval were Mary Ann Forciea, MD† (); Michael J. Dobbin Chow, MD, MBA‡; Nick Fitterman, MD‡; Russell P. Humphrey, MD, MPH‡; Devan Kansagara, MD, MCR‡; Scott Manaker, MD, Ph D†; Robert Mc Lean, MD‡; Sandeep Vijan, MD, MS†; and Timothy Wilt, MD, MPH‡.
Approved by the ACP Board of Regents on 7 November 2015.
The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness of treatment with second-generation antidepressants versus nonpharmacologic treatments for major depressive disorder in adults.